Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


The T-SPOT.TB test now included in new CDC guidelines
TB blood tests preferred for targeted groups

Oxford, UK [Marlborough, MA]; 25 June 2010 - Oxford Immunotec Inc, announces the release of new Centers for Disease Control and Prevention (CDC) guidelines for using interferon gamma release assays (IGRA) to detect Mycobacterium tuberculosis infection. For the first time, the CDC make specific recommendations for which an IGRA is preferred over use of the 100+ year-old tuberculin skin test (TST), including persons who have received the BCG vaccination, and for persons unlikely to return for the required reading of results needed to complete the test.

A significant percentage of the approximately 20 million individuals tested for TB infection in the U.S. each year fall into the two groups for which an IGRA is now preferred. Use of IGRA tests such as the T-SPOT.TB test are expected to reduce false positives and unnecessary treatment, as well as increase the acceptance of treatment by those truly infected with TB.

In addition, the new guidelines recommend that the T-SPOT.TB test may now be used in place of the tuberculin skin test (TST) in all situations in which the CDC recommends tuberculin skin testing. Since obtaining premarket approval from the Food and Drug Administration (FDA) in July 2008, the T-SPOT.TB test has become widely utilized in hospitals, medical practices and public health facilities throughout the United States. The T-SPOT.TB test is backed by the clinical evidence of over 200 peer-reviewed publications, and is the only IGRA with both sensitivity and specificity exceeding 95% in FDA pivotal trials.

When asked about the guidelines, Dr. Peter Wrighton-Smith, CEO of Oxford Immunotec said, “We strongly support the new recommendations the CDC has made, and believe they will have a positive impact on TB control in the U.S. The targeted use of IGRA’s provides compelling clinical and economic benefits, and hundreds of institutions have already adopted the T-SPOT.TB test for this purpose. We’re pleased to be part of the solution in the global effort to eliminate TB.”

Notes to Editors:

About Oxford Immunotec
Oxford Immunotec Ltd., the T cell measurement company, is headquartered near Oxford, UK; its US operations are based in Marlborough, MA. The company develops and sells clinical diagnostic products based on its patented T-SPOT® technology, the first FDA-approved method for directly quantifying antigen-specific T cells.
T-SPOT technology is a simple and extremely accurate method of studying a person’s cellular immune response to infection and could be applied to diagnose and monitor any major disease driven by a T cell response.

About T-SPOT®.TB test
The T-SPOT.TB test is an in vitro T cell measurement assay used for diagnosing TB disease and latent TB infection and is the first product from Oxford Immunotec using T-SPOT technology. The product offers unrivalled sensitivity with results unaffected by a patient’s immune status. The T-SPOT.TB test is approved for sale in Europe, USA, Canada and over 40 other countries worldwide and is designed to replace the 115 year old tuberculin skin test. It offers a substantially more accurate and effective tool for controlling the spread of TB, addressing a market exceeding $1bn.

At Oxford Immunotec:
Dr Peter Wrighton-Smith, CEO Tel: +44 (0)1235 442780 Fax: +44 (0)1235 442781 Email:
Oxford Immunotec 94c Milton Park Abingdon Oxfordshire OX14 4RY, UK
Oxford Immunotec Inc, 2 Mount Royal Avenue, Marlborough, MA 01752

Publisher Contact Information:

Oxford Immunotec Ltd.
+44 (0)1235 442780

Company profile of Oxford Immunotec Ltd.
Past press releases of Oxford Immunotec Ltd..


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
Jul 31€2.8MInternet services
Jul 30€9.5MWireless applications
Jul 30€4.5MSensors
Jul 30€5.0ME-Commerce
Jul 30N/ANetwork management
Jul 30€72.0MInternet services

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Mar 31
the fit allocates chf 100'000 to comppair technologies

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.